Your Source for Venture Capital and Private Equity Financings

Venture Capital News: ROME Therapeutics Launches with $50M Series A

2020-04-27
CAMBRIDGE, MA, ROME Therapeutics launched today with $50M in Series A funding from GV, ARCH Venture Partners and Partners Innovation Fund.
ROME Therapeutics, a biotechnology company harnessing the power of the repeatome in drug development, launched today with $50 million in Series A funding from GV, ARCH Venture Partners and Partners Innovation Fund. ROME was founded to discover and develop novel therapies for cancer and autoimmune diseases by leveraging new insights from the vast uncharted territory of the repeatome; the roughly 60% of the human genome consisting of repetitive sequences of nucleic acids, known as repeats. Drawing on deep expertise in oncology, virology, immunology and machine learning, the ROME team has identified several promising drug targets and launched multiple discovery programs.

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome; vast stretches of uncharted genetic material that have long been dismissed as 'junk DNA.' With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning. ROME was launched in April 2020 and was incubated at GV, in collaboration with ARCH Venture Partners and Partners Innovation Fund.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors